Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus ROCEPHIN.
FORTAZ vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic